Synopsis
Recognise the rapid tempo of small-cell lung cancer, secure efficient tissue and staging, and coordinate platinum-based systemic therapy, radiotherapy and urgent complication management.
- Small-cell lung cancer is a high-grade neuroendocrine malignancy with early dissemination, rapid doubling and initial treatment sensitivity followed by a substantial risk of relapse.
- Obtain pathological confirmation promptly, but design one efficient diagnostic and staging sequence because serial low-yield procedures can consume a clinically important treatment window.
- Use TNM staging and also describe limited-stage disease when it can be encompassed within a tolerable radical radiotherapy field; extensive-stage disease exceeds that practical boundary.
Key red flags
Seizure, new focal neurology, altered consciousness or raised-intracranial-pressure features requires urgent brain imaging and acute management before routine outpatient staging.
Investigation priorities
Define primary, nodal, hepatic, adrenal and other accessible disease before sampling.
Management branches
Imaging or clinical tempo suggests central high-grade lung cancer compatible with SCLC.
- Identify immediate airway, neurological, metabolic and venous-obstruction emergencies, treating these in parallel with diagnostic planning and early acute-oncology contact.
- Use contrast CT to select one safe high-yield biopsy route, often bronchoscopic or EBUS for central disease, and alert pathology that rapid definitive classification is needed.
Key medicines
Platinum plus etoposideIntravenous combination cycles prescribed by oncology protocol with organ-function adjustment and supportive medicines.
AtezolizumabIntravenous specialist schedule with induction combination then maintenance according to the licensed pathway.